Targeting CDK6 and BCL2 Exploits the "MYB Addiction" of Ph + Acute Lymphoblastic Leukemia

Philadelphia chromosome-positive acute lymphoblastic leukemia (Ph ALL) is currently treated with BCR-ABL1 tyrosine kinase inhibitors (TKI) in combination with chemotherapy. However, most patients develop resistance to TKI through BCR-ABL1-dependent and -independent mechanisms. Newly developed TKI ca...

Celý popis

Podrobná bibliografia

Vydané v:	Cancer research (Chicago, Ill.) Ročník 78; číslo 4; s. 1097
Hlavní autori:	De Dominici, Marco, Porazzi, Patrizia, Soliera, Angela Rachele, Mariani, Samanta A, Addya, Sankar, Fortina, Paolo, Peterson, Luke F, Spinelli, Orietta, Rambaldi, Alessandro, Martinelli, Giovanni, Ferrari, Anna, Iacobucci, Ilaria, Calabretta, Bruno
Médium:	Journal Article
Jazyk:	English
Vydavateľské údaje:	United States 15.02.2018
Predmet:	Animals Cyclin-Dependent Kinase 6 - genetics Cyclin-Dependent Kinase 6 - metabolism Humans Mice Precursor Cell Lymphoblastic Leukemia-Lymphoma - genetics Precursor Cell Lymphoblastic Leukemia-Lymphoma - metabolism Precursor Cell Lymphoblastic Leukemia-Lymphoma - pathology Proto-Oncogene Proteins c-bcl-2 - genetics Proto-Oncogene Proteins c-bcl-2 - metabolism
ISSN:	1538-7445, 1538-7445
On-line prístup:	Zistit podrobnosti o prístupe
Tagy:	Pridať tag Žiadne tagy, Buďte prvý, kto otaguje tento záznam!